Redundancy between cysteine cathepsins in murine experimental autoimmune encephalomyelitis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Allan, Euan Ramsay Orr ^a   Yates, Robin Michael ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; CATHEPSIN; CYSTEINE; DIPEPTIDE; HLA ANTIGEN CLASS 2; N-MORPHOLINOUREA-LEUCINE-HOMOPHENYLALANINE-PHENYL-VINYLSULFONE; SULFONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; FLUOROMETRY; GENE EXPRESSION PROFILING; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENETICS; IMMUNOLOGY; METABOLISM;

MURINAE; MUS;

ANIMALS; ANTIGEN PRESENTATION; CATHEPSINS; CD4-POSITIVE T-LYMPHOCYTES; CYSTEINE; DIPEPTIDES; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; MACROPHAGES; MALE; MICE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; SULFONES;

EID: 84936991055     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128945     Document Type: Article

References (51)

1. Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007; 13(4):387-403. Epub 2007/02/22. PMID: 17311556.
2. Haves-Zburof D, Paperna T, Gour-Lavie A, Mandel I, Glass-Marmor L, Miller A. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med. 2011; 15(11):2421-9. Epub 2010/12/15. doi: 10.1111/j.1582-4934.2010.01229.x PMID: 21143385.
3. Stoeckle C, Quecke P, Ruckrich T, Burster T, Reich M, Weber E, et al. Cathepsin S dominates autoantigen processing in human thymic dendritic cells. J Autoimmun. 2012; 38(4):332-43. Epub 2012/03/20. doi: 10.1016/j.jaut.2012.02.003S0896-8411(12)00026-1 [pii]. PMID: 22424724.
4. Beers C, Honey K, Fink S, Forbush K, Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med. 2003; 197(2):169-79. Epub 2003/01/23. PMID: 12538657; PubMed Central PMCID: PMC2193812.
5. Honey K, Duff M, Beers C, Brissette WH, Elliott EA, Peters C, et al. Cathepsin S regulates the expression of cathepsin L and the turnover of gamma-interferon-inducible lysosomal thiol reductase in B lymphocytes. J Biol Chem. 2001; 276(25):22573-8. Epub 2001/04/18. doi: 10.1074/jbc.M101851200M101851200 [pii]. PMID: 11306582.
6. Nakagawa T, Roth W, Wong P, Nelson A, Farr A, Deussing J, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998; 280(5362):450-3. Epub 1998/05/09. PMID: 9545226.
7. Nakagawa TY, Brissette WH, Lira PD, Griffiths RJ, Petrushova N, Stock J, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity. 1999; 10(2):207-17. Epub 1999/03/11. doi: S1074-7613(00)80021-7 [pii]. PMID: 10072073.
8. Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol. 2002; 3(2):169-74. Epub 2002/01/29. doi: 10.1038/ni754ni754 [pii]. PMID: 11812994.
9. Belizaire R, Unanue ER. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc Natl Acad Sci U S A. 2009; 106(41):17463-8. Epub 2009/10/07. doi: 10.1073/pnas.09085831060908583106 [pii]. PMID: 19805168; PubMed Central PMCID: PMC2752404.
10. Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun. 2011; 36(3-4):201-9. Epub 2011/03/29. doi: 10.1016/j.jaut.2011.01.003S0896-8411(11)00010-2 [pii]. PMID: 21439785.
11. Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev. 2005; 207:229-41. Epub 2005/09/27. doi: IMR310 [pii]doi: 10.1111/j.0105-2896.2005.00310.x PMID: 16181340.
12. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest. 1998; 101(11):2351-63. Epub 1998/06/17. doi: 10.1172/JCI1158 PMID: 9616206; PubMed Central PMCID: PMC508824.
13. Honey K, Nakagawa T, Peters C, Rudensky A. Cathepsin L regulates CD4+ T cell selection independently of its effect on invariant chain: a role in the generation of positively selecting peptide ligands. J Exp Med. 2002; 195(10):1349-58. Epub 2002/05/22. PMID: 12021314; PubMed Central PMCID: PMC2193748.
14. Lockwood TD. Cathepsin B responsiveness to glutathione and lipoic acid redox. Antioxid Redox Signal. 2002; 4(4):681-91. Epub 2002/09/17. doi: 10.1089/15230860260220193 PMID: 12230881.
15. Desai SN, White DM, O'Shea K M, Brown ML, Cywin CL, Spero DM, et al. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity. Eur J Pharmacol. 2006; 538(1-3):168-74. Epub 2006/04/25. doi: S0014-2999(06)00322-0 [pii]doi: 10.1016/j.ejphar.2006.03.051 PMID: 16631730.
16. Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol. 2008; 38(9):2401-11. Epub 2008/09/16. doi: 10.1002/eji.200838413 PMID: 18792018.
17. Liuzzo JP, Petanceska SS, Devi LA. Neurotrophic factors regulate cathepsin S in macrophages and microglia: A role in the degradation of myelin basic protein and amyloid beta peptide. Mol Med. 1999; 5(5):334-43. Epub 1999/07/03. doi: 0130 [pii]. PMID: 10390549; PubMed Central PMCID: PMC2230424.
18. Beck H, Schwarz G, Schroter CJ, Deeg M, Baier D, Stevanovic S, et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol. 2001; 31(12):3726-36. Epub 2001/12/18. doi: 10.1002/1521-4141(200112)31:12〈3726::AID-IMMU3726〉3.0.CO;2-O [pii]10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O. PMID: 11745393.
19. Bever CT Jr., Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology. 1994; 44(4):745-8. Epub 1994/04/01. PMID: 8164836.
20. Hsieh CS, deRoos P, Honey K, Beers C, Rudensky AY. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol. 2002; 168(6):2618-25. Epub 2002/03/09. PMID: 11884425.
21. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol. 2009; 9(6):393-407. Epub 2009/05/16. doi: 10.1038/nri2550 PMID: 19444307; PubMed Central PMCID: PMC2813731.
22. Nakahara J, Aiso S, Suzuki N. Autoimmune versus oligodendrogliopathy: the pathogenesis of multiple sclerosis. Arch Immunol Ther Exp (Warsz). 2010; 58(5):325-33. Epub 2010/08/03. doi: 10.1007/s00005-010-0094-x PMID: 20676785.
23. Yamasaki R, Lu H, Butovsky O, Ohno N, Rietsch AM, Cialic R, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med. 2014; 211(8):1533-49. Epub 2014/07/09. doi: 10.1084/jem.20132477jem.20132477 [pii]. PMID: 25002752; PubMed Central PMCID: PMC4113947.
24. Stromnes IM, Goverman JM. Active induction of experimental allergic encephalomyelitis. Nat Protoc. 2006; 1(4):1810-9. Epub 2007/05/10. doi: 10.1038/nprot.2006.285 PMID: 17487163.
25. Podolin PL, Bolognese BJ, Carpenter DC, Davis TG, Johanson RA, Fox JH, et al. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor. J Immunol. 2008; 180(12):7989-8003. Epub 2008/06/05. doi: 180/12/7989 [pii]. PMID: 18523262.
26. Irie O, Kosaka T, Kishida M, Sakaki J, Masuya K, Konishi K, et al. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg Med Chem Lett. 2008; 18(19):5280-4. Epub 2008/09/12. doi: 10.1016/j.bmcl.2008.08.067S0960-894X(08)00997-9 [pii]. PMID: 18783943.
27. Lee-Dutra A, Wiener DK, Sun S. Cathepsin S inhibitors: 2004-2010. Expert Opin Ther Pat. 2011; 21(3):311-37. Epub 2011/02/24. doi: 10.1517/13543776.2011.553800 PMID: 21342054.
28. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A. 1998; 95(8):4516-21. Epub 1998/05/16. PMID: 9539769; PubMed Central PMCID: PMC22521.
29. Shi GP, Villadangos JA, Dranoff G, Small C, Gu L, Haley KJ, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity. 1999; 10(2):197-206. Epub 1999/03/11. doi: S1074-7613(00)80020-5 [pii]. PMID: 10072072.
30. Rybicka JM, Balce DR, Chaudhuri S, Allan ER, Yates RM. Phagosomal proteolysis in dendritic cells is modulated by NADPH oxidase in a pH-independent manner. EMBO J. 2011; 31(4):932-44. Epub 2011/12/14. doi: 10.1038/emboj.2011.440 PMID: 22157818; PubMed Central PMCID: PMC3280544.
31. Rybicka JM, Balce DR, Khan MF, Krohn RM, Yates RM. NADPH oxidase activity controls phagosomal proteolysis in macrophages through modulation of the lumenal redox environment of phagosomes. Proc Natl Acad Sci U S A. 2010; 107(23):10496-501. Epub 2010/05/26. doi: 10.1073/pnas.0914867107 PMID: 20498052; PubMed Central PMCID: PMC2890838.
32. Savina A, Jancic C, Hugues S, Guermonprez P, Vargas P, Moura IC, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006; 126(1):205-18. PMID: 16839887.
33. Karasuyama H, Melchers F. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988; 18(1):97-104. Epub 1988/01/01. doi: 10.1002/eji.1830180115 PMID: 2831066.
34. Allan ER, Tailor P, Balce DR, Pirzadeh P, McKenna NT, Renaux B, et al. NADPH Oxidase Modifies Patterns of MHC Class II-Restricted Epitopic Repertoires through Redox Control of Antigen Processing. J Immunol. 2014; 192(11):4989-5001. Epub 2014/04/30. doi: 10.4049/jimmunol.1302896jimmunol.1302896 [pii]. PMID: 24778444.
35. van der Veen RC, Dietlin TA, Hofman FM, Pen L, Segal BH, Holland SM. Superoxide prevents nitric oxide-mediated suppression of helper T lymphocytes: decreased autoimmune encephalomyelitis in nicotinamide adenine dinucleotide phosphate oxidase knockout mice. J Immunol. 2000; 164(10):5177-83. Epub 2000/05/09. PMID: 10799876.
36. Agrawal SM, Silva C, Tourtellotte WW, Yong VW. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci. 2011; 31(2):669-77. Epub 2011/01/14. doi: 10.1523/JNEUROSCI.3659-10.201131/2/669 [pii]. PMID: 21228176.
37. Balce DR, Li B, Allan ER, Rybicka JM, Krohn RM, Yates RM. Alternative activation of macrophages by IL-4 enhances the proteolytic capacity of their phagosomes through synergistic mechanisms. Blood. 2011; 118(15):4199-208. Epub 2011/08/19. doi: 10.1182/blood-2011-01-328906 PMID: 21846901.
38. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J Neurochem. 1973; 21(4):749-57. Epub 1973/10/01. PMID: 4271082.
39. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J Exp Med. 2003; 197(9):1073-81. Epub 2003/05/07. doi: 10.1084/jem.20021603 PMID: 12732654; PubMed Central PMCID: PMC2193967.
40. Balce DR, Allan ER, McKenna N, Yates RM. gamma-Interferon-inducible lysosomal thiol reductase (GILT) maintains phagosomal proteolysis in alternatively activated macrophages. J Biol Chem. 2014; 289(46):31891-904. Epub 2014/09/26. doi: 10.1074/jbc.M114.584391M114.584391 [pii]. PMID: 25253686; PubMed Central PMCID: PMC4231668.
41. Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK. Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo. J Neurochem. 2005; 95(6):1755-65. Epub 2005/10/13. doi: JNC3503 [pii]doi: 10.1111/j.1471-4159.2005.03503.x PMID: 16219027.
42. Underhill DM, Bassetti M, Rudensky A, Aderem A. Dynamic interactions of macrophages with T cells during antigen presentation. J Exp Med. 1999; 190(12):1909-14. Epub 1999/12/22. PMID: 10601366; PubMed Central PMCID: PMC2195713.
43. Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol. 2003; 81:331-71. Epub 2004/01/09. PMID: 14711059.
44. Govindarajan KR, Clausen J. Regional distribution of cathepsins B 1 and D in human brain. Brain Res. 1974; 67(1):141-6. Epub 1974/02/15. doi: 0006-8993(74)90304-7 [pii]. PMID: 4470412.
45. Govindarajan KR, Offner H, Clausen J, Fog T, Hyllested K. The lymphocytic cathepsins B-1 and D activities in multiple sclerosis. J Neurol Sci. 1974; 23(1):81-7. Epub 1974/09/01. doi: 0022-510X(74)90144-0 [pii]. PMID: 4854938.
46. Kikuchi H, Yamada T, Furuya H, Doh-ura K, Ohyagi Y, Iwaki T, et al. Involvement of cathepsin B in the motor neuron degeneration of amyotrophic lateral sclerosis. Acta Neuropathol. 2003; 105(5):462-8. Epub 2003/04/05. doi: 10.1007/s00401-002-0667-9 PMID: 12677446.
47. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med. 1997; 186(4):549-60. Epub 1997/08/18. PMID: 9254653; PubMed Central PMCID: PMC2199027.
48. Gresser O, Weber E, Hellwig A, Riese S, Regnier-Vigouroux A. Immunocompetent astrocytes and microglia display major differences in the processing of the invariant chain and in the expression of active cathepsin L and cathepsin S. Eur J Immunol. 2001; 31(6):1813-24. Epub 2001/07/04. doi: 10.1002/1521-4141(200106)31:6〈1813::AID-IMMU1813〉3.0.CO;2-8 [pii]10.1002/1521-4141(200106)31:6<1813::AID-IMMU1813>3.0.CO;2-8. PMID: 11433378.
49. Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol. 2003; 25(1):3-18. Epub 2003/08/09. doi: 10.1007/s00281-003-0127-1 PMID: 12904888.
50. Fujii H, Ivison SM, Shimizu H, Kajiwara R, Kariminia A, Yan M, et al. Inhibition of cathepsin S reduces allogeneic T cell priming but not graft-versus-host disease against minor histocompatibility antigens. Biol Blood Marrow Transplant. 2012; 18(4):546-56. Epub 2011/12/20. doi: 10.1016/j.bbmt.2011.11.027S1083-8791(11)00543-X [pii]. PMID: 22178962.
51. Boehme DH, Umezawa H, Hashim G, Marks N. Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin). Neurochem Res. 1978; 3(2):185-94. Epub 1978/04/01. PMID: 307703.